CRISPR Therapeutics CRSP Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from CRISPR Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's return on assets?
- CRISPR Therapeutics (CRSP) reported return on assets of -23.2% in Q1 2026.
- How has CRISPR Therapeutics's return on assets changed year-over-year?
- CRISPR Therapeutics's return on assets decreased by 38.8% year-over-year, from -16.7% to -23.2%.
- What is the long-term trend for CRISPR Therapeutics's return on assets?
- Over 3 years (2020 to 2025), CRISPR Therapeutics's return on assets has grown at a 2.3% compound annual growth rate (CAGR), from -24.1% to -25.8%.
- What does return on assets mean?
- Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.